• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Venus Concept Inc.

    6/11/25 4:05:18 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Venus Concept Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    92332W303

    (CUSIP Number)


    06/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92332W303


    1Names of Reporting Persons

    Orca Capital AG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    108,680.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    108,680.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    108,680.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 1,859,123 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering as described in the Issuer's filings with the Securities and Exchange Commission, and excludes 217,360 shares of Common Stock issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Common Stock (the "4.99% Blocker").


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Venus Concept Inc.
    (b)Address of issuer's principal executive offices:

    235 YORKLAND BLVD. SUITE 900 TORONTO A6 M2J4Y8
    Item 2. 
    (a)Name of person filing:

    Orca Capital AG
    (b)Address or principal business office or, if none, residence:

    Sperlring 2 85276 Hettenshausen Deutschland
    (c)Citizenship:

    Germany
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    92332W303
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    108,680
    (b)Percent of class:

    5.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    108,680

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    108,680

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orca Capital AG
     
    Signature:/s/ Thomas Konig
    Name/Title:Thomas Konig/Director
    Date:06/11/2025
    Get the next $VERO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    SEC Filings

    View All

    SEC Form 15-12G filed by Venus Concept Inc.

    15-12G - Venus Concept Inc. (0001409269) (Filer)

    2/9/26 7:15:41 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    7/2/25 7:27:23 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    4/2/25 5:47:31 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Venus Concept Announces Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device ("EBD") revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter. Primarily driven by a decline in the Hair Restoration business (the "Venus Hair Business") impacted by a delay in the pending sale. Third

    11/13/25 7:00:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments

    TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology -delivering a powerful, comprehensive solution for body contouring, muscle co

    11/10/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP ("Madryn") for 545,335 shares of its Series Y preferred stock. Following the transaction, the Company had total debt obligations of approximately $30.1 million, a reduction of 24% compared to $39.7 million outstanding as of December 31, 2024. "Madryn's invaluable partnership has provided us with financial flexibility as we work towards sustained long

    10/2/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care